【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 6
2 Pharmaceutical & Healthcare, Global, Deals Summary 9
2.1 Pharmaceutical & Healthcare, Global, Deals Analysis, 2012 9
2.1.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, 2012 by Quarter 11
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, 2012 13
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, 2012 14
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, 2012 15
2.5 Pharmaceuticals & Healthcare, Top Deals, Global, Summaries, 2012 16
2.5.1 Abbott Completes Private Placement of Notes for $14.7 Billion 16
2.5.2 Nestle Completes Acquisition of Pfizer Nutrition from Pfizer for $11.85 Billion 16
2.5.3 Roche Revises Offer Price to Acquire Illumina for Up To $8.2 Billion 16
2.5.4 Aetna Receives Shareholders Approval to Acquire Coventry Health Care for $7.3 Billion 17
2.5.5 Walgreen Acquires 45% Stake in Alliance Boots from KKR And AXA Private Equity for $6.7 Billion 17
2.5.6 Watson Pharma Completes Acquisition of Actavis Group for $5.92 Billion 18
2.5.7 Bristol-Myers Squibb Completes Acquisition of Amylin Pharma for $5.3 Billion 19
2.5.8 GlaxoSmithKline Completes Public Offering of Notes for $5 Billion 19
2.5.9 UnitedHealth Completes Acquisition of 60% Stake in Amil Participacoes 19
2.5.10 WellPoint Completes Acquisition of Amerigroup for $4.9 Billion 20
3 Pharmaceuticals & Healthcare, Global, Top Deal Makers, 2012 21
4 Pharmaceuticals & Healthcare, Global, Deal Summary, by Type 22
4.1 Pharmaceuticals & Healthcare, Global, M&A, 2012 22
4.1.1 Pharmaceuticals & Healthcare, Global, M&A, 2012 by Quarter 23
4.1.2 Top M&A Deals in 2012 24
4.1.3 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, 2012 25
4.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2012 26
4.2.1 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2012 by Quarter 27
4.2.2 Pharmaceuticals & Healthcare, Global, IPO Deals, 2012 28
4.2.3 Pharmaceuticals & Healthcare, Global, Secondary Offerings Deals, 2012 30
4.2.4 Pharmaceuticals & Healthcare, Global, PIPE Deals, 2012 32
4.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, 2012 34
4.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, 2012 35
4.3.1 Pharmaceuticals & Healthcare, Global Debt Offerings, 2012 by Quarter 36
4.3.2 Pharmaceuticals & Healthcare, Global, Public Debt Offerings, 2012 37
4.3.3 Pharmaceuticals & Healthcare, Global, Private Debt Placements, 2012 38
4.3.4 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, 2012 39
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2012 40
4.4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2012 by Quarter 41
4.4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, 2012 43
4.4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Value (US$ m), 2012 44
4.4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), 2012 45
4.4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, 2012 46
4.4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), 2012 47
4.4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 2012 48
4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2012 51
4.5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2012 by Quarter 52
4.5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, 2012 53
4.5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Upfront & Milestone Payments and Deal Value (US$ m), 2012 54
4.5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), 2012 55
4.5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), 2012 56
4.5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), 2012 57
4.5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 2012 58
4.6 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2012 61
4.6.1 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2012 by Quarter 62
4.6.2 Top Private Equity Deals in 2012 63
4.6.3 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, 2012 64
4.7 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, 2012 65
4.7.1 Pharmaceuticals & Healthcare, Global, Venture Financing Deals, 2012 by Quarter 66
4.7.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, 2012 67
4.7.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, 2012 68
4.7.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, 2012 69
4.7.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Last One Year 70
4.7.6 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, 2012 71
4.7.7 Top Venture Financing Deals in 2012 72
5 Pharmaceuticals & Healthcare, Global, Deal Summary, By Market 73
5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2012 73
5.1.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2012 by Quarter 75
5.1.2 Oncology – Deals of the Year 76
5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2012 78
5.2.1 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2012 by Quarter 79
5.2.2 Central Nervous System – Deals of the Year 80
5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2012 82
5.3.1 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2012 by Quarter 83
5.3.2 Infectious Disease – Deals of the Year 84
5.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2012 86
5.4.1 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2012 by Quarter 87
5.4.2 Immunology – Deals of the Year 88
5.5 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2012 90
5.5.1 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2012 by Quarter 91
5.5.2 Cardiovascular – Deals of the Year 92
5.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2012 93
5.6.1 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2012 by Quarter 94
5.6.2 Metabolic Disorders – Deals of the Year 95
5.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2012 97
5.7.1 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2012 by Quarter 98
5.7.2 Gastrointestinal – Deals of the Year 99
6 Pharmaceuticals & Healthcare, Deal Summary, By Geography 101
6.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2012 101
6.1.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2012 by Quarter 102
6.1.2 North America – Deals of the Year 103
6.2 Pharmaceuticals & Healthcare, European Region Deals, 2012 106
6.2.1 Pharmaceuticals & Healthcare, Europe, Deals, 2012 by Quarter 107
6.2.2 Europe – Deals of the Year 108
6.3 Pharmaceuticals & Healthcare, Asia-Pacific Region, Deals, 2012 110
6.3.1 Pharmaceuticals & Healthcare, Asia-Pacific Region Deals, 2012 by Quarter 111
6.3.2 Asia-Pacific – Deals of the Year 112
6.4 Pharmaceuticals & Healthcare, Rest of the World (ROW) Deals, 2012 114
6.4.1 Pharmaceuticals & Healthcare, Rest of the World Deals, 2012 by Quarter 115
6.4.2 Rest of the World – Deals of the Year 116
7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 117
7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, 2012 117
7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, 2012 118
8 Further Information 119
8.1 Methodology 119
8.2 About GlobalData 120
8.3 Contact Us 120
8.4 Disclosure information 120
8.5 Disclaimer 120
【レポート販売概要】
■ タイトル：Pharmaceutical & Healthcare Annual Deals Analysis: M&A and Investments Trends – 2012■ 英文：Pharmaceutical & Healthcare Annual Deals Analysis: M&A and Investments Trends - 2012
■ 発行日：2013年3月31日
■ 調査会社：GlobalData
■ 商品コード：GDATA403160699
■ 調査対象地域：グローバル
- UAEの防衛市場動向Summary The Future of the UAE Defense Industry - Market Attractiveness, Competitive Landscape and Forecasts to 2019 published by Strategic Defence Intelligence, provides readers with a detailed analysis of both historic and forecast UAE defense industry values, factors influencing demand, the challenges faced by industry participants, analysis of industry leading companies and key news. Key Findin …
- EV Energy Partners, L.P.社の石油・ガス開発・生産動向及びコスト分析（2013年第4四半期）EV Energy Partners, L.P. Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2013 Summary EV Energy Partners, L.P. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential …
- AWE Limited：石油・ガスの開発・生産動向及びコスト分析– 2012AWE Limited Oil & Gas Exploration and Production Operations and Cost Analysis – 2012 Summary AWE Limited Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key operational dat …
- 潰瘍(Ulcers)：世界の治験レビュー（2015年上半期版）Ulcers Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Ulcers Global Clinical Trials Review, H1, 2015" provides an overview of Ulcers clinical trials scenario. This report provides top line data relating to the clinical trials on Ulcers. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The re …
- 流体管理システムの世界市場予測2021：透析器、注入器、流体加温装置、圧力変換器、吸収缶The fluid management systems and accessories market is projected to reach USD 12.47 Billion by 2021 from USD 9.39 Billion in 2016, at a CAGR of 5.8% during the forecast period. Factors such as increasing number of minimally invasive surgeries, technological advancements in fluid management systems, and increase in government funds and grants worldwide for endosurgical procedures are driving the ma …
- タンタル及びニオブ（コロンビウム）の世界市場動向2014/2015The report presents a thorough study of tantalum and niobium (columbium), covering both global and regional markets. It aims to give a proper picture of the market, its trends, perspectives and opportunities. Comprehensive data showing tantalum and niobium (columbium) worldwide production, consumption, trade statistics and prices are provided. Each country’s market overview covers the following: t …
- 脳内出血治療のグローバル臨床試験動向（2014年H2）Intracerebral Hemorrhage Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Intracerebral Hemorrhage Global Clinical Trials Review, H2, 2014" provides data on the Intracerebral Hemorrhage clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Intracerebral Hemorrhage. It includes an overview of the trial num …
- 世界の塩水脱塩市場動向（2012-2016）TechNavio's analysts forecast the Global Water Desalination market to grow at a CAGR of 9.51 percent over the period 2012-2016. One of the key factors contributing to this market growth is the need for safe water. The Global Water Desalination market has also been witnessing increased governmental initiatives in the Water industry. However, the possibility of water desalination putting the ocean e …
- 電子顕微鏡の世界市場2016-2020About Electron Microscope An electron microscope is a scientific instrument that uses an electron beam to illuminate and enlarge objects under observation. It is mainly used to study miniature and high-density objects such as microchips and find defects in metal sheets used in the steel, automobile, and aerospace industries. Electron microscopes are also used to a large extent in microbiological a …
- French Hospital Microbiology Testing Market 2014This new report from Venture Planning Group contains 897 pages, 77 tables, and presents a comprehensive analysis of the French hospital microbiology testing market, including: Major issues pertaining to the French hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. Curre …
- イギリスの人工甘味料市場2015-2019The artificial sweetener market is expected to register a moderate growth rate during the forecast period. Technavio's market research analysts project the artificial sweetener market in the UK to reach USD 93.87 million by the year 2019. The rising demand for natural sweeteners such as stevia and the declining demand for diet soft drinks, which are the primary users of artificial sweeteners, can …
- 末梢血管装置（医療機器）のグローバル市場（2012-2018）Global Peripheral Vascular Devices sector forecasts to reach US$5 billion by 2016 at a CAGR of 10.8% during the analysis period 2012-2018. North American region accounts for highest percentage approximately 42% (2015) of global share while Europe follows next with nearly 27.7% (2018) of the market. Asia-Pacific is the fastest growing region with a CAGR of 12.5% driving a market value of US$1 billi …
- Bill Barrett Corporation：石油・ガスの開発・生産動向及びコスト分析- Q2, 2013Bill Barrett Corporation Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary Bill Barrett Corporation Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential …
- 石油・ガスのインフラセキュリティ市場予測（2014-2024）The oil and gas infrastructure security market will experience steady growth over the next 10 years. The unconventional oil and gas boom, the expansion of the LNG infrastructure supply chain, continued offshore developments and the emergence of the digital oilfield are all prime factors for new security solution spending. Visiongain has assessed that global expenditure on oil and gas infrastructur …
- 世界の薬剤管理システム市場動向（2012-2016）TechNavio’s analysts forecast the Global Medication Management System market to grow at a CAGR of 5.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is increase in aging population. The Global Medication Management System market has also been witnessing the trend of increase in mergers and acquisitions. However, reluctance of patients to adopt medicat …
